# US 2006/0188920 A1 · Identification of compounds that inhibit replication of human immunodeficiency virus

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0188920 A1
- Document ID: US20060188920A1
- Status: Published application
- Kind: A1
- Application number: 11/409,671
- Filed: 2006-04-24
- Published: 2006-08-24
- Earliest claimed: 2003-02-21
- Inventors: Jan Maria Balzarini; Anders Vahlne; Marita Hogberg; Weimin Tong
- Web page: https://patentgrep.com/patent/US20060188920A1

## CPC

- C07C 237/06: having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- A61K 31/164: of a carboxylic acid with an aminoalcohol, e.g. ceramides
- A61P 31/18: for HIV
- B01D 15/362: {Cation-exchange}
- B01D 15/34: Size-selective separation, e.g. size-exclusion chromatography; Gel filtration; Permeation
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- B01D: SEPARATION (separating solids from solids by wet methods B03B, B03D; by pneumatic jigs or tables B03B; by other dry methods B07; magnetic or electrostatic separation of solid materials from solid materials or fluids, separation by high-voltage electric fields B03C; centrifuges, vortex apparatus B04; presses per se for squeezing-out liquid from liquid-containing material B30B9/02; treatment of water C02F, e.g. softening by ion-exchange C02F1/42; {arrangements of air intake cleaners in gas turbine plants F02C7/05} ; arrangements or mounting of filters in air-conditioning, air-humidification or ventilation F24F13/28)

## Abstract

The present invention relates to the discovery of a novel class of compounds that inhibit the replication of human immunodeficiency virus (HIV) and approaches to identify these compounds. More specifically, it has been found that enzymatically prepared alpha-hydroxyglycinamide and synthetically prepared alpha-hydroxyglycinamide inhibit the replication of HIV in human serum. Embodiments include methods to identify modified glycinamide compounds that inhibit HIV, methods to isolate and synthesize modified glycinamide compounds, and therapeutic compositions comprising these compounds.

## Claims

### Claim 1

A pharmaceutical or medicament comprising as an active ingredient, with or without other active ingredients, a compound of formula A:
or a pharmaceutically acceptable salt, amide, or ester thereof;
wherein
a) E is selected from the group consisting of oxygen, sulfur, and NR7;
b) T is selected from the group consisting of oxygen, sulfur, and NR8;
c) R1—R8 are each independently selected from the group consisting of hydrogen; optionally substituted alkyl; optionally substituted alkenyl; optionally substituted alkynyl; optionally substituted cycloalkyl; optionally substituted heterocyclyl; optionally substituted cycloalkylalkyl; optionally substituted heterocyclylalkyl; optionally substituted aryl; optionally substituted heteroaryl; optionally substituted alkylcarbonyl; optionally substituted alkoxyalkyl; and optionally substituted perhaloalkyl; wherein said compound is in an amount effective to inhibit HIV replication.
